Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest in this topic

  1. Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial 2025-05-20
  2. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial 2019-11-25
  3. The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway 2017-07-01

Studies

5 studies carry this tag.

Date range

2010 to 2025

Top journals

  • Antioxidants & redox signaling 1
  • CNS drugs 1
  • Communications medicine 1
  • GeroScience 1
  • Oxidative medicine and cellular longevity 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Communications medicine 2025-05-20 Biomarkers

    Rapamycin is not detectable in the CSF before or after treatment, but several Alzheimer's disease and inflammatory biomarkers increase after treatment.

  2. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. GeroScience 2019-11-25 Clinical trials

    Aging is a major risk factor for the majority of human diseases, and the development of interventions to reduce the intrinsic rate of aging is expected to reduce the risk for age-related diseases including cardiovascular disease, cancer, and dementia.

  3. The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. CNS drugs 2017-07-01 Drug development

    The mechanistic target of rapamycin (mTOR) is an important molecule that connects aging, lifespan, energy balance, glucose and lipid metabolism, and neurodegeneration.

  4. Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder and represents one of the most disabling conditions.

  5. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Oxidative medicine and cellular longevity 2010-11-01 Brain scans and imaging

    The mammalian target of rapamycin (mTOR) and its associated cell signaling pathways have garnered significant attention for their roles in cell biology and oncology.

All topic tags with their study counts